Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 10/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 5/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17488243 | 0.93 | PLK4 (0.42) | PLK4NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL17488023 | 0.86 | CYP3A4 (0.47) | PLK4NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL17487841 | 0.86 | DHODH (0.43) | PLK4NPC1RAB9ANTRK1 | |
| SCHEMBL17488026 | 0.85 | NTRK1 (0.47) | PLK4NPC1RAB9ASMN1; SMN2PAK4 | |
| SCHEMBL18965934 | 0.85 | GSK3B (0.40) | PLK4NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL17487846 | 0.85 | LMNA (0.41) | PLK4SMN1; SMN2RETPAK4NTRK1 | |
| SCHEMBL17487531 | 0.83 | PLK4 (0.41) | PLK4NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL17488140 | 0.83 | PIK3C3 (0.40) | NPC1RAB9AKMT2ASMN1; SMN2RET | |
| SCHEMBL17488142 | 0.83 | PLK4 (0.38) | PLK4NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL17487532 | 0.82 | PLK4 (0.40) | PLK4PAK4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| WO-2016016421-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | PLK4 3683/4885NPC1 2764/4885RAB9A 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.